Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 246 participants.

Also called NCT06813911

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 246 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06813911
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, China, France, Germany, Hong Kong SAR China, Italy, Netherlands, Puerto Rico, Spain, Taiwan, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06813911. Randomized; double masking; primary purpose treatment. Start 2025-04-30 (actual); primary completion 2028-02-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
Acronym
ADD-VANTAGE
Condition
Atherosclerotic Cardiovascular Disease (ASCVD)
Intervention (Drug)
Pelacarsen
Intervention (Drug)
Placebo
Intervention (Drug)
Inclisiran
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct06813911
Content hash
41f9a25dc591cbd30f5d930f81e17b64a531ad12fe660f5488cff40484705e62